COVID-19 Seroprevalence Study in French Guiana
EPI-COVID-POP
1 other identifier
interventional
3,541
1 country
5
Brief Summary
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2020
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 15, 2020
CompletedFirst Submitted
Initial submission to the registry
July 28, 2020
CompletedFirst Posted
Study publicly available on registry
July 29, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 24, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 24, 2021
CompletedFebruary 15, 2022
February 1, 2022
1.2 years
July 28, 2020
February 14, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Measure of the COVID-19 immunity of the population
The COVID-19 immunity of the population will be assessed by evaluating the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies
1 year
Secondary Outcomes (1)
Evaluation of the level of asymptomatic and pauci-symptomatic infections
1 year
Study Arms (1)
Participants
EXPERIMENTALBlood sample
Interventions
Eligibility Criteria
You may qualify if:
- Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;
- State of health compatible with a blood sample as defined in the protocol
You may not qualify if:
- Inability to consent
- Person under guardianship or curatorship
- Known pathology or a health problem contraindicated with the collect of blood sample.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Institut Pasteurlead
- Institut Pasteur de la Guyanecollaborator
- Laboratoire de biologie médicale, Institut Pasteur de la Guyanecollaborator
- Laboratoire de biologie médicale de Kourou, French Guianacollaborator
- Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guianacollaborator
- Eurofinscollaborator
- Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guianacollaborator
Study Sites (5)
Centre Hospitalier Andrée Rosemon
Cayenne, French Guiana
Laboratoire de biologie méicale, Institut Pasteur de la Guyane
Cayenne, French Guiana
Laboratoires Eurofins Guyane
Cayenne, French Guiana
Laboratoire de biologie médicale de Kourou
Kourou, French Guiana
Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni
Saint-Laurent-du-Maroni, French Guiana
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Claude Flamand, PhD
Institut Pasteur de la Guyane, Head of Epidemiology Unit
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 28, 2020
First Posted
July 29, 2020
Study Start
July 15, 2020
Primary Completion
September 24, 2021
Study Completion
September 24, 2021
Last Updated
February 15, 2022
Record last verified: 2022-02